Literature DB >> 16127435

PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.

Domingo F Barber1, Almira Bartolomé, Carmen Hernandez, Juana M Flores, Clara Redondo, Cristina Fernandez-Arias, Montserrat Camps, Thomas Rückle, Matthias K Schwarz, Santiago Rodríguez, Carlos Martinez-A, Dimitrios Balomenos, Christian Rommel, Ana C Carrera.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by deregulation of T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure. Disease is treated with immunosuppressants and cytostatic agents that have numerous side effects. Here we examine the use of inhibitors of phosphoinositide 3-kinase (PI3K) gamma, a lipid kinase that regulates inflammation, in the MRL-lpr mouse model of SLE. Treatment reduced glomerulonephritis and prolonged lifespan, suggesting that P13Kgamma may be a useful target in the treatment of chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127435     DOI: 10.1038/nm1291

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  97 in total

Review 1.  Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Authors:  Wolfgang Poller; Madlen Rother; Carsten Skurk; Carmen Scheibenbogen
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Biological therapy for lupus nephritis-tribulations and trials.

Authors:  Rona M Smith; Menna R Clatworthy; David R W Jayne
Journal:  Nat Rev Rheumatol       Date:  2010-07-20       Impact factor: 20.543

Review 3.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

4.  Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.

Authors:  John Doukas; Wolfgang Wrasidlo; Glenn Noronha; Elena Dneprovskaia; Richard Fine; Sara Weis; John Hood; Anthony Demaria; Richard Soll; David Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

Review 5.  New players in TLR-mediated innate immunity: PI3K and small Rho GTPases.

Authors:  Monica Ruse; Ulla G Knaus
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 6.  Decompartmentalizing target validation-thinking outside the pipeline boxes.

Authors:  Rob Hooft van Huijsduijnen; Christian Rommel
Journal:  J Mol Med (Berl)       Date:  2006-08-05       Impact factor: 4.599

Review 7.  Phosphoinositide 3-kinase controls early and late events in mammalian cell division.

Authors:  Zaira García; Amit Kumar; Miriam Marqués; Isabel Cortés; Ana C Carrera
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

8.  The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites.

Authors:  Molly S Thomas; Jason S Mitchell; Christopher C DeNucci; Amanda L Martin; Yoji Shimizu
Journal:  J Leukoc Biol       Date:  2008-06-03       Impact factor: 4.962

9.  Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma.

Authors:  Barbara Kurig; Aliaksei Shymanets; Thomas Bohnacker; Carsten Brock; Mohammad Reza Ahmadian; Michael Schaefer; Antje Gohla; Christian Harteneck; Matthias P Wymann; Elisabeth Jeanclos; Bernd Nürnberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

10.  Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.

Authors:  Mauro Siragusa; Rajesh Katare; Marco Meloni; Federico Damilano; Emilio Hirsch; Costanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2010-01-07       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.